IdentifySensors Biologics (identifysensors.com) has developed graphene-based, solid-state biosensors that electronically detect multiple infections simultaneously from a single saliva sample. The tests instantly detect and differentiate DNA and RNA among a group of targeted pathogens through an unmistakable digital signal – all with the accuracy and sensitivity intended to exceed PCR tests.
The technology has been incorporated into a portable Bluetooth device that connects to health system databases. The process is entirely electronic with no chemical amplification or reagents. It eliminates the need for trained clinicians, who normally administer and process PCR tests. The tests are intended to significantly disrupt the PCR market through lower pricing, greater accessibility for use and multiplex testing, with rapid, digital results.
IdentifySensors has started large-scale production with East West Manufacturing in Wisconsin. The devices will be submitted to the FDA in early 2024 for both Rx and consumer use. Testing targets, along with clinical trials in the first two years include Strep, Flu A and Flu B, COVID, RSV, diarrheal pathogens, STDs, HIV, Lyme, Ebola, Marburg and Hepatitis C. The company is in discussions with several large bio-tech firms for partnerships and sales.
Ready to Ask For Funding for your company?
Post a Funding Request